MDM2 and non-small cell lung carcinoma: Regarding important therapeutic opportunities in NSCLC, for wt TP53 LUAD, the elevated expression levels of MDM2 and MDM4 (Figure 8A,B) in these cancers predict that these patients are likely to benefit from treatment with dual inhibitors of the MDM family (e.g., Aileron [54]).